Articles

Vantage logo

Novocure aims to plough a new field

Lung cancer approval for the group’s electric fields-based therapy could come this year, but Novocure has broader solid tumour ambitions.

Vantage logo

Novartis trims its pipeline

Discontinuations for branaplam, iptacopan and Piqray could increase pipeline scepticism, but more pruning is coming.

Vantage logo

Astrazeneca gets personal

A collaboration this week with the blood testing specialist Capitainer underlines the big pharma’s ambition to have a diagnostic linked with every pipeline project.

Vantage logo

The end of the Humira era

With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?

Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.